coteauBeta Get App

OPCH

Option Care Health
$31.29
+0.00% Oct 22 close
Health CareS&P 400 CompareTechnicals
1M3M6M1Y2Y
-31%-16%-1%+15%+30%Oct 2025Oct 2026Apr 2026
OPCHSPY
1W
+0.2%
1M
+30.9%
3M
+48.4%
6M
+9.6%
YTD
-1.8%
1Y
+10.6%

Live chart

Loading live chart…

What they do

Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapy and services; home infusion services to treat heart failure. It also offers treatments to manage the progression of neurological disorders, such as Duchenne muscular dystrophy, multiple sclerosis, Alzheimer's disease.

Healthcare · Medical Care Facilities

For information only · Important disclosures

Grades vs sector

Momentum
19th percentile in sector
D
12-1 return: -13.6%
Percentile within its GICS sector across the S&P 1500.
Growth
17th percentile in sector
D
Revenue growth (YoY): +1.9%
Percentile within its GICS sector across the S&P 1500.
Value
62nd percentile in sector
B-
Forward E/P: 6.7% · EBITDA/EV: 7.1%
Percentile within its GICS sector across the S&P 1500.
Profitability
50th percentile in sector
C+
Profit margin: +3.7% · Return on equity: +16.0%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Our models

Not held by any of our 5 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 Coteau Long Book
Not in the current book

News

More news
Strength Seen in Option Care (OPCH): Can Its 32.7% Jump Turn into More Strength?
Zacks · Oct 07

Key stats

52-week range$19.52 – $36.59
Valuation and fundamentals

Valuation & fundamentals

Bottom line
Roughly fairly valued
Model read-out from the numbers below, not advice. Score +0 (DCF counts double).
•DCF (base case)above the price by 1%
•Piotroski F-score5/9
•Net debt / EBITDA2.5x

Discounted cash flow

Bear
$17
-46%
growth 8% · disc. 10.2% · term. 2.0%
Base
$31
+1%
growth 13% · disc. 9.2% · term. 2.5%
Bull
$52
+66%
growth 17% · disc. 8.2% · term. 3.0%

A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.

Reverse DCFfor context, not a signal
Not enough data to run a reverse DCF.
Edit assumptions · recalculates instantly
Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2025-03-31). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.00 (n/a) × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs Health Care

P/E (trailing)
sector median 29.9×
 –
Forward P/E
sector median 17.6×
 –
EV / EBITDA
sector median 15.8×
 –
Price / sales
sector median 3.1×
 –
Price / book
sector median 3.5×
 –
FCF yield
sector median 4.1%
 –

Quality & financial health

Gross margin
21.0%
Operating margin
6.4%
FCF margin
4.1%
Net margin
4.0%
Return on equity
15.3%
Return on invested capital
10.4%
Net debt / EBITDA
2.5×
Current ratio
1.6×
Interest cover
6.1×
Cash conversion (OCF/NI)
1.2×
Piotroski F-score 5/9 · last two fiscal years
✓ Positive net income✓ Positive operating cash flow✗ Return on assets improved✓ Cash flow above net income✗ Long-term debt / assets fell✗ Current ratio improved✓ No share dilution✗ Gross margin improved✓ Asset turnover improved

Analysts

No analyst targets available.

Annual history

FYRevenueNet incomeFree cash flow
2025$5.6B$207.6M$217.1M
2024$5.0B$211.8M$287.8M
2023$4.3B$267.1M$329.4M
2022$3.9B$150.6M$232.2M
2021$3.4B$139.9M$182.9M
2020$3.0B$-8.1M$100.5M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +13.4%.

Earnings

Next report: 2026-11-04 · before open · EPS est 0.49
24-1025-0225-0425-0725-1026-0226-0426-070.000.47
EstimateActual (beat)Actual (miss)
ReportEPS estActualSurprise
2026-07-290.430.45+5.4%
2026-04-300.370.40+8.1%
2026-02-240.470.46-1.8%
2025-10-300.430.45+4.7%
2025-07-300.400.41+3.3%
2025-04-290.340.40+19.0%
2025-02-260.370.37-0.2%
2024-10-300.320.33+4.4%

Quarterly revenue

QuarterRevenueYoY
2026-06-30$1.4B+1.9%
2026-03-31$1.4B–
2025-12-31$1.5B–
2025-09-30$1.4B–
2025-06-30$1.4B–
Rating changes
Downgrade
2026-10-09 · UBS downgraded OPCH from Buy to Neutral
Downgrade
2026-10-07 · William Blair downgraded OPCH from Outperform to Market Perform
Downgrade
2026-10-07 · JP Morgan downgraded OPCH from Overweight to Neutral
Downgrade
2026-10-07 · Citizens downgraded OPCH from Market Outperform to Market Perform
Downgrade
2026-10-07 · Jefferies downgraded OPCH from Buy to Hold
Downgrade
2026-10-07 · Barrington Research downgraded OPCH from Outperform to Market Perform

Third-party analyst actions, not Coteau's views. All rating changes

Stats refreshed 2026-10-21 18:01:44 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Free. Not investment advice. Unsubscribe anytime.

coteau

Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksTermsPrivacyData statusSend feedback
Beta 0.9 · Oct 21, 2026